Latest News

JACKSONVILLE, Florida — A rare cause of hereditary cognitive decline known as CSF1R-Related Disorder (CSF1R-RD) gets its name from mutations in the CSF1R gene, discovered by Mayo Clinic. Memory loss occurs as the condition advances, while early symptoms include personality changes, anxiety, depression and loss of inhibition. Genetic testing has...
WASHINGTON, DC — A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized phase II study will be presented today at the American Society for...
ROCHESTER, Minn. — New research from Mayo Clinic finds that patients with lymphedema —swelling of the limbs caused by the accumulation of protein-rich fluids of the immune system — had twice the risk of developing skin cancer than patients without lymphedema. Patients with lymphedema had a significantly higher frequency of developing basal cell carcinomas and squamous cell...
ROCHESTER, Minn. — Researchers have discovered a novel molecular path that predisposes patients to develop primary biliary cirrhosis, a disease that mainly affects women and slowly destroys their livers. Primary biliary cirrhosis has no known cause. The finding, significant because it is a first step toward developing a targeted treatment...
Montreal, Quebec – A new study from a team of McGill University and Vanderbilt University researchers is shedding light on our understanding of the molecular origins of some forms of autism and intellectual disability. For the first time, researchers were able to successfully capture atomic resolution images of the fast-moving ionotropic...
HOUSTON and SOUTH SAN FRANCISCO, Calif. ― The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers. The alliance brings together MD Anderson’s clinical research expertise with...
HOUSTON, Texas and MIAMI, Florida ― The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab. Leveraging MD Anderson’s clinical infrastructure and research expertise together with Summit’s innovative, investigational, potential first-in-class PD-1/VEGF...